Stock comparison
Haemonetics
Harrow Health
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
HROW
Harrow Health
Market cap
$1.23B
Sector
Healthcare
Overall winner
Harrow Health HROW
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | HROW | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 54C | HAE |
| Benjamin Graham | 85A | 73D | HAE |
| Philip Fisher | 60C | 65C | HROW |
| Peter Lynch | 54C | 75C | HROW |
| Joel Greenblatt | 31F | 47D | HROW |
| Charlie Munger | 54D | 55D | HROW |
| Terry Smith | 55D | 49D | HAE |
Side-by-side metrics
| Metric | HAE | HROW |
|---|---|---|
| Market cap | $2.98B | $1.23B |
| P/E (TTM) | 24.8x | - |
| EV/EBIT | 14.1x | 35.2x |
| ROIC (TTM) | 8.37% | 8.55% |
| Gross margin | 55.74% | 74.11% |
| Net margin | 7.29% | -5.57% |
| Revenue CAGR 5y | 7.65% | 39.22% |
| EPS CAGR 5y | 24.62% | - |
| Debt / Equity | 1.5x | 10.5x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- Net margin7.29%vs -5.57%+176%
- Debt / Equity1.5xvs 10.5x+85%
- EV/EBIT14.1xvs 35.2x+60%
- Market cap$2.98Bvs $1.23B+59%
HROW leads on
- P/E (TTM)-vs 24.8x+132%
- Revenue CAGR 5y39.22%vs 7.65%+80%
- Gross margin74.11%vs 55.74%+25%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.